Safety and Tolerability Study of Liquid Alpha1 Proteinase Inhibitor (API) in Subjects With Cystic Fibrosis

NCT01347190 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

BIOLOGICAL: CR002 Liquid API
BIOLOGICAL: Placebo

Sponsor

CSL Behring